stockrowNutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025.
- Revenue
- −29.7%
- EPS
- +96.7%
- Free cash flow
- +55.5%
- Total debt
- −46.9%
Quarter to July 2026, against a year earlier
Follow NTRB
Alert me
Nutriband Inc. (NTRB) EV/Sales
As of 6 November 2026, Nutriband Inc. (NTRB) trades at a EV/Sales of 39.8×. Over the past ten years it has ranged from 0.0× (July 2019) to 417× (July 2019); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 24.6× | (37.13%) |
| FY2025 | 39.1× | 299.84% |
| FY2024 | 9.8× | (29.94%) |
| FY2023 | 14.0× | (20.59%) |
| FY2022 | 17.6× | (84.04%) |
| FY2021 | 110× | (45.26%) |
| FY2020 | 201× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 19.4× | (19.10%) |
| Apr 2026 | 23.9× | (2.77%) |
| Jan 2026 | 24.6× | (26.16%) |
| Oct 2025 | 33.3× | 16.11% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNXU Conexeu Sciences Inc. compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| COYA Coya Therapeutics, Inc. compare | 4.9× |
| RANI Rani Therapeutics Holdings, Inc. compare | 12.6× |
| NTRB Nutriband Inc. | 39.8× |
| MNOV MediciNova, Inc. compare | 50.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)